Tag
GLP-1 drugs are the center of the modern weight-loss and diabetes conversation. This tag collects plain-language explainers and research updates about what these medicines do, what the evidence says, and what still isn’t known.
New review, real-world, and animal data point to a less glamorous GLP‑1 question: not just whether obesity drugs work, but what repeated interruption, restart, and weight cycling could mean for long-term care.
A randomized Nature Medicine trial found that once-daily oral orforglipron helped people maintain more of their prior injectable GLP‑1 weight loss than placebo, pointing to a future where obesity treatment may include step-down maintenance strategies.
A randomized Lancet trial found that semaglutide plus therapy reduced heavy drinking days in people with alcohol use disorder and obesity, adding momentum to the idea that GLP‑1 drugs may affect reward behavior as well as weight.
A large EHR-based preprint links semaglutide to lower rates of many neuropsychiatric diagnoses, with a ‘legacy’ signal that tracks maximum achieved dose more than weight loss.
A new observational study links GLP‑1 therapy to lower atrial fibrillation risk even when people do not lose weight, with the strongest signal reported for semaglutide.
A large real-world analysis links GLP‑1 plus SGLT2 combination therapy to lower rates of major liver and cardiovascular events in people with fatty liver disease and type 2 diabetes.
A translational study links cholesterol-pathway inhibition (HMGCR/rosuvastatin) to lower acute GLP‑1 secretion in gut cells and mice, offering a plausible mechanism behind statins’ mild diabetes signal.
A new supportive-care commentary argues that as GLP‑1 drugs become common, cancer treatment teams may need routine nutrition and body-composition monitoring to avoid avoidable toxicity and dose changes.
A new mechanistic study shows SNAC, the absorption enhancer used in oral semaglutide, changes state with pH, salts, bile, and co-medications—conditions that may shape oral peptide consistency.
A large matched TriNetX study found prior GLP‑1 receptor agonist exposure was associated with fewer infections, less ICU care, and lower mortality after smaller thermal burns, but it cannot prove cause and effect.
A large register study using two comparator cohorts plus a self-controlled design found no increased rate of suicide or suicide attempts after starting GLP‑1 receptor agonists.
In an in vitro rat brainstem-spinal cord setup, exendin-4 increased sympathetic nerve activity and depolarized key neurons, supporting a direct neural route for GLP-1 receptor agonist tachycardia.
In diabetic mice, a long-acting, fatty-acid–conjugated GLP-1 receptor agonist showed measurable effects when held under the tongue for about five minutes after the team tuned pH and excipients.
A 2026 umbrella review of prior meta-analyses reports GLP‑1 receptor agonists are associated with lower major adverse cardiovascular events and less ‘worsening heart failure’, plus a small improvement in 6‑minute walk distance. Mortality and heart-failure hospitalization results were not clearly improved, and evidence certainty ranged low to moderate.
A Medicare target-trial emulation found similar thyroid-stimulating hormone (TSH) testing patterns after GLP-1 receptor agonist initiation versus SGLT-2 inhibitors in older adults on stable levothyroxine, despite weight loss often changing thyroid hormone requirements.
A systematic review and meta-analysis of 21 placebo-controlled trials in patients at increased cardiovascular risk found no clear difference in serious adverse events with tirzepatide, while gastrointestinal side effects remained more common. Mortality evidence was sparse.